Locally advanced and metastatic

Cancer staging can feel very complicated, so please ask your doctor to explain in more detail why it matters and what your stage means for you.1

Home  | Locally advanced and metastatic

This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib)

Home  | Locally advanced and metastatic

Locally advanced and metastatic

Cancer staging can feel very complicated, so please ask your doctor to explain in more detail why it matters and what your stage means for you.1

Osimertinib is a targeted therapy for locally advanced and metastatic late-(stage 4) EGFR+ NSCLC2-4

Locally advanced EGFR+ NSCLC is stage 3 disease where the cancer has not spread to other organs, and is treated with osimertinib where surgery is not an option.

Your NSCLC tested positive for a certain EGFR biomarker, which is why you and your doctor chose this drug.2

Osimertinib is a targeted therapy, which means it is a treatment that specifically attacks EGFR and blocks the growth and spread of lung cancer cells.2-4

Targeted therapies are not chemotherapy or immunotherapy.5

Talk to your healthcare professional about the importance of staying on track with your osimertinib treatment to help prevent your lung cancer from growing or spreading.3

Always keep communicating with your doctor and healthcare team so they know how you’re doing with your treatment. Be aware of any changes that you notice in your body and let them know if/ when you experience any side effects.3

 

Stage 4 image
Stage 4 image

Adjuvant
therapy

Understand what your staging means for you

References:

  1. Cancer Research UK (CRUK). Stages and grades of lung cancer. Last reviewed: 28 Jan 2020. Available at: https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types-grades/stages-grades Accessed December 2023. 
  2. Tagrisso 40 mg and 80 mg film coated tablets. Summary of product characteristics.
  3. Tagrisso 40 mg and 80 mg film coated tablets. Patient Information Leaflet.
  4. Nakashima K, Ozawa Y, et al. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Invest New Drugs. 2020;38(6):1854-1861. 
  5. NIH. Targeted Therapy to Treat Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies#what-is-targeted-therapy Accessed December 2023.


GB-73016  I  DOP: January 2026

This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib), which is indicated after surgery in adults with stage 1B-3A NSCLC with a particular EGFR mutation, and also in locally advanced or metastatic NSCLC with a particular EGFR mutation. It does not replace the Patient Information Leaflet, which you can find in the carton containing your medicine and which you should read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.